<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965535</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-0121</org_study_id>
    <secondary_id>2013-002296-17</secondary_id>
    <nct_id>NCT01965535</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks With Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV)
      fixed-dose combination (FDC) with and without ribavirin (RBV), and to evaluate the safety
      and tolerability of each regimen as assessed by review of the accumulated safety data.
      Approximately 150 participants with genotype 1 HCV infection, who have previously received
      treatment for HCV, and who have a diagnosis for cirrhosis will be enrolled. Participants
      will be randomized to 1 of 2 groups.

      Group 1: SOF/LDV FDC tablet plus placebo to match RBV for 24 weeks

      Group 2: Delayed treatment group: placebo to match SOF/LDV FDC plus placebo to match RBV for
      12 weeks, followed by SOF/LDV FDC once daily plus RBV in a divided daily dose for 12 weeks

      Randomization will 1:1 to the two groups and will be stratified by HCV genotype (1a, 1b;
      mixed or other genotype 1 results will be stratified as genotype 1a), and prior HCV therapy
      treatment response (never achieved HCV RNA &lt; the lower limit of quantitation [LLOQ], or
      achieved HCV RNA &lt; LLOQ).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>Post-treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as hepatitis C virus (HCV) RNA &lt; LLOQ 12 weeks after discontinuation of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV RNA &lt; LLOQ at 4 weeks (SVR4) and 24 weeks (SVR24) post-treatment.</measure>
    <time_frame>Post-treatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV RNA &lt; LLOQ while on treatment</measure>
    <time_frame>Baseline to Weeks 4, 12, and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of participants with HCV RNA &lt; LLOQ at Weeks 4, 12, and 24 (or early termination) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HCV RNA</measure>
    <time_frame>Baseline to Weeks 4, 12, 24, and post-treatment Weeks 4, 12, and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with virologic failure</measure>
    <time_frame>Weeks 4, 12, and 24, and post-treatment Weeks 4, 12, and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure is defined as virologic breakthrough (participant achieved undetectable HCV RNA levels during treatment but subsequently had detectable HCV RNA while continuing treatment) or relapse (participant achieved undetectable HCV RNA levels during treatment maintained undetectable HCV RNA for the duration of treatment or achieved undetectable HCV RNA within 4 weeks of the end of treatment but did not achieve SVR at 4, 12, or 24 weeks post-treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>SOF/LDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF/LDV FDC tablet, plus placebo to match RBV for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF/LDV + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delayed treatment group: participants will receive placebo to match SOF/LDV FDC, plus placebo to match RBV for 12 weeks, followed by SOF/LDV FDC once daily, plus RBV in a divided daily dose for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/LDV</intervention_name>
    <description>SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily</description>
    <arm_group_label>SOF/LDV</arm_group_label>
    <arm_group_label>SOF/LDV + RBV</arm_group_label>
    <other_name>Sofosbuvir</other_name>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Ledipasvir</other_name>
    <other_name>GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing &lt; 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)</description>
    <arm_group_label>SOF/LDV + RBV</arm_group_label>
    <other_name>Ribavirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match SOF/LDV</intervention_name>
    <arm_group_label>SOF/LDV + RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match RBV</intervention_name>
    <arm_group_label>SOF/LDV</arm_group_label>
    <arm_group_label>SOF/LDV + RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or greater than 18 years, with chronic genotype 1 HCV infection

          -  HCV RNA ≥ 10,000 IU/mL at Screening

          -  Prior virological failure after treatment with PEG-interferon (IFN), RBV and a
             protease inhibitor following documented prior virology failure after treatment with a
             PEG-IFN + RBV regimen

          -  Evidence of cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  Prior exposure to approved or experimental HCV specific direct-acting antivirals
             (DAA[s]) other than a nonstructural protein (NS)3/4A protease inhibitor

          -  History of solid organ transplantation, including liver transplant

          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain
             resolved skin cancers)

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Hyland, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>57037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpelier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 24, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
